MX358474B - Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. - Google Patents

Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.

Info

Publication number
MX358474B
MX358474B MX2014012306A MX2014012306A MX358474B MX 358474 B MX358474 B MX 358474B MX 2014012306 A MX2014012306 A MX 2014012306A MX 2014012306 A MX2014012306 A MX 2014012306A MX 358474 B MX358474 B MX 358474B
Authority
MX
Mexico
Prior art keywords
prognosis
parkinson
alzheimer
diseases
monitoring
Prior art date
Application number
MX2014012306A
Other languages
English (en)
Other versions
MX2014012306A (es
Inventor
Balwant Rai
Jasdeep Kaur
Original Assignee
Oasis Diagnostics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oasis Diagnostics Corp filed Critical Oasis Diagnostics Corp
Publication of MX2014012306A publication Critical patent/MX2014012306A/es
Publication of MX358474B publication Critical patent/MX358474B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/926—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método de diagnóstico in vitro de la enfermedad de Alzheimer, caracterizado porque comprende los pasos de: probar una muestra de saliva para niveles de un grupo de biomarcadores que consiste de IGF-I, IGF-II, Aß-40, Aß-42, alfa amilasa, IL-1 beta y TNF-alfa; y determinar que la muestra de saliva es positiva para la enfermedad de Alzheimer si los niveles del grupo de biomarcadores pasan todos los criterios en un grupo de criterios de prueba que consiste de; nivel de Aß-40 inferior a un nivel de referencia de Aß-40, nivel de TNF. Alfa superior a un nivel de referencia de TNF-alfa, nivel de IL-1 beta superior a un nivel de referencia de IL-1 beta, nivel de Aß-42 superior a un nivel de referencia de Aß-42, nivel de IGF-I inferior a un nivel de referencia de IGF-I, nivel de IGF-II inferior a un nivel de referencia de IG-II, y nivel de alfa-amilasa superior a un nivel de referencia de alfa-amilasa.
MX2014012306A 2012-04-13 2013-04-12 Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. MX358474B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1138DE2012 2012-04-13
PCT/IB2013/001407 WO2013153461A2 (en) 2012-04-13 2013-04-12 Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases

Publications (2)

Publication Number Publication Date
MX2014012306A MX2014012306A (es) 2015-05-07
MX358474B true MX358474B (es) 2018-08-21

Family

ID=48998640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012306A MX358474B (es) 2012-04-13 2013-04-12 Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.

Country Status (5)

Country Link
EP (2) EP2836844B1 (es)
AU (2) AU2013246621A1 (es)
CA (1) CA2877975C (es)
MX (1) MX358474B (es)
WO (1) WO2013153461A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11112405B1 (en) 2020-05-18 2021-09-07 Baseline Global, Inc. Assay device, system, method, and kit

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067699A1 (en) 2015-03-11 2016-09-14 Neuron Bio, S.A. Method for diagnosing alzheimer's disease
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
ES2657414T3 (es) * 2015-11-20 2018-03-05 Geroa Diagnostics, S.L Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer
JP2019525176A (ja) * 2016-07-28 2019-09-05 アウリン バイオテック インコーポレイテッド アルツハイマー病についての予後指標としての唾液中Ａｂｅｔａ４２レベル
EP3312611B1 (en) 2016-10-21 2020-02-26 Dr. Power Stem Biomedical Research Inc., Ltd. Method for diagnosis of alzheimer's disease
EP3376230A1 (en) 2017-03-13 2018-09-19 Biocross, S.L. Identification of signatures for neurodegeneration diseases diagnoses
LT3752836T (lt) 2018-02-14 2023-02-10 Salignostics Ltd. Sudėtinių dalių aptikimo būdai ir aparatas
CN111781376A (zh) * 2020-07-08 2020-10-16 东南大学深圳研究院 一种阿尔茨海默病生物标志物的快速检测方法
WO2022087694A1 (pt) * 2020-10-26 2022-05-05 Frans Eduardo Diagnóstico de alzheimer vía saliva utilizando o método lateral flow assay
EP4237857A1 (en) * 2020-10-30 2023-09-06 Baseline Global, Inc. Methods, systems, and kits for prediction, detection, monitoring, and treatment of alzheimer's disease
CN113687082A (zh) * 2021-08-19 2021-11-23 中国大冢制药有限公司 β淀粉样蛋白低聚物的检测方法、检测β淀粉样蛋白低聚物的试剂盒及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728605A (en) 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
EP0760098A4 (en) 1994-06-09 1997-07-16 Univ Bar Ilan DIAGNOSIS OF THE LEVEL OF ALZHEIMER DISEASES THROUGH MONONUCLEAR CELL CYTOKININ SECRETION
US5686269A (en) 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
AUPO943297A0 (en) 1997-09-24 1997-10-16 University Of Melbourne, The Diagnostic test for alzheimer's disease
US6358681B2 (en) 1998-10-30 2002-03-19 The Trustees Of The University Of Pennsylvania Diagnostic methods for alzheimer's disease by detection of multiple mRNAs
CA2269432C (en) 1998-06-01 2002-04-02 Hyman M. Schipper Ho-1 as a diagnostic and prognostic test for dementing diseases
AU2610901A (en) 1999-12-30 2001-07-16 Washington University Predictive diagnostic for alzheimer's disease
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US6475161B2 (en) 2001-03-29 2002-11-05 The Mclean Hospital Corporation Methods for diagnosing Alzheimer's disease and other forms of dementia
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US7344853B2 (en) 2003-01-27 2008-03-18 Baylor College Of Medicine Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
US7598049B2 (en) 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
WO2005072398A2 (en) 2004-01-28 2005-08-11 Bamburgh Marrsh Llc Specimen sample collection device and test system
US7927548B2 (en) 2005-01-27 2011-04-19 Bamburgh Marsh Llc Specimen sample collection device and test system
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
US7833513B2 (en) * 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP2008537143A (ja) 2005-04-19 2008-09-11 バーミリオン， インコーポレイテッド アルツハイマー病のためのバイオマーカーであるサポシンｄ及びｆａｍ３ｃ
WO2007106762A2 (en) 2006-03-14 2007-09-20 Washington University In St. Louis Alzheimer's disease biomarkers and methods of use
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20080261226A1 (en) 2007-02-15 2008-10-23 Rengang Wang Biomarkers of neurodegenerative disease
US20090061457A1 (en) 2007-09-05 2009-03-05 Power3 Medical Products, Inc. Apolipoprotein E3 protein as a biomarker of Parkinson's disease
US20100167937A1 (en) 2008-07-08 2010-07-01 Power3 Medical Products, Inc. Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11112405B1 (en) 2020-05-18 2021-09-07 Baseline Global, Inc. Assay device, system, method, and kit

Also Published As

Publication number Publication date
EP2836844A2 (en) 2015-02-18
CA2877975C (en) 2021-09-21
AU2019200241A1 (en) 2019-01-31
EP3255435A1 (en) 2017-12-13
MX2014012306A (es) 2015-05-07
WO2013153461A3 (en) 2014-05-15
WO2013153461A2 (en) 2013-10-17
EP2836844B1 (en) 2017-08-16
AU2013246621A1 (en) 2014-11-27
CA2877975A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
HK1214652A1 (zh) 用於检测胰腺癌的方法和组合物
EP3194624A4 (en) Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
NZ606725A (en) Methods for predicting anti-cancer response
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
MX2023005452A (es) Deteccion de beta amiloide por espectrometria de masas.
HK1206423A1 (en) Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
EP3098311A4 (en) Method for measuring modified nucleobase using guide probe, and kit therefor
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
EP3216879A4 (en) Pna probe, kit and method for detecting human papillomavirus genotype
NZ729773A (en) Biomarkers for disease progression in melanoma
MA40636A (fr) Procédés pour détecter le cancer de la prostate
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
WO2015013455A3 (en) Methods and compositions for the treatment and diagnosis of cancer
EP3088895A4 (en) Method for analyzing information for diagnosis and kit therefor

Legal Events

Date Code Title Description
FG Grant or registration